Actualités

Schrödinger, Inc. (NASDAQ:SDGR) is among the Best Pharmaceutical Stocks. On May 14, Morgan Stanley lowered its price target on Schrödinger, Inc. (NASDAQ:SDGR) to $17 from $19. The firm maintained an “Equal Weight” rating on the shares. Separately, Schrödinger, Inc. (NASDAQ:SDGR) maintained full-year guidance for ACV of $218 million to $228 million. The corporation expects 10% to […]

Schrödinger’s fair value estimate has been trimmed slightly from US$21.38 to US$20.88, bringing it in line with the updated implied price target in the model. This mirrors recent Street research, where several firms have also cut price targets while stressing that the shift reflects refreshed views on valuation, revenue recognition and execution risks rather than a single catalyst. As you read on, you will see how these moving targets shape the evolving analyst narrative and what to watch...

Schrödinger’s fair value estimate has been trimmed from US$23.50 to US$21.38, a move that lines up with a wider round of price target cuts across the Street. Analysts tying these changes to the growing mix of hosted software point to short term noise in reported revenue and investor perception, even as some maintain Buy ratings and focus on underlying usage trends. As you read on, you will see how to track these shifting targets and what they may signal for the evolving Schrödinger...